Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer is a special type of breast cancer with poor prgnosis and
limited choices. Chemotherapy is the only choice of adjuvant systemic treatment options.
Previous study suggested that zoledronic acid might have anti-tumor effect by eliminating the
number of DTCs(Disseminated Tumor Cell )and had been proved to be effective as adjvant
therapy in postmenopausal women whose breast cancer was Homonal receptor positive and who
were receiving aromatase inhibitors. So it might be able to improve the survival of triple
negative breast cancer patients.